Analysts predict that Agios Pharmaceuticals Inc (NASDAQ:AGIO) will announce ($1.73) earnings per share (EPS) for the current quarter, Zacks reports. Five analysts have made estimates for Agios Pharmaceuticals’ earnings, with estimates ranging from ($1.91) to ($1.59). Agios Pharmaceuticals posted earnings per share of ($1.19) in the same quarter last year, which would indicate a negative year-over-year growth rate of 45.4%. The firm is expected to announce its next earnings report on Thursday, August 1st.
On average, analysts expect that Agios Pharmaceuticals will report full year earnings of ($6.76) per share for the current fiscal year, with EPS estimates ranging from ($7.57) to ($6.13). For the next financial year, analysts forecast that the business will report earnings of ($6.40) per share, with EPS estimates ranging from ($7.50) to ($5.44). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Agios Pharmaceuticals.
Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.59) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.74) by $0.15. The business had revenue of $30.20 million during the quarter, compared to the consensus estimate of $22.69 million. Agios Pharmaceuticals had a negative net margin of 300.63% and a negative return on equity of 48.19%. The firm’s revenue for the quarter was up 243.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.63) earnings per share.
A number of research analysts have recently commented on AGIO shares. BidaskClub downgraded shares of Agios Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, May 9th. Piper Jaffray Companies decreased their price objective on shares of Agios Pharmaceuticals from $100.00 to $85.00 and set an “overweight” rating for the company in a research report on Friday, May 3rd. Zacks Investment Research downgraded shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, April 25th. ValuEngine cut shares of Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, April 18th. Finally, Cowen restated a “buy” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, March 13th. Two analysts have rated the stock with a sell rating, four have given a hold rating and eight have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $95.83.
Agios Pharmaceuticals stock traded down $1.00 during mid-day trading on Wednesday, reaching $46.83. The company’s stock had a trading volume of 215,425 shares, compared to its average volume of 582,629. The company has a market cap of $2.74 billion, a P/E ratio of -7.77 and a beta of 2.25. Agios Pharmaceuticals has a 12 month low of $41.63 and a 12 month high of $99.82. The company has a current ratio of 6.89, a quick ratio of 6.86 and a debt-to-equity ratio of 0.11.
In other Agios Pharmaceuticals news, insider Christopher Bowden sold 10,000 shares of the firm’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $64.16, for a total value of $641,600.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Scott Biller sold 3,000 shares of the firm’s stock in a transaction dated Friday, April 5th. The shares were sold at an average price of $67.71, for a total transaction of $203,130.00. Following the completion of the transaction, the insider now directly owns 29,511 shares in the company, valued at $1,998,189.81. The disclosure for this sale can be found here. Insiders sold a total of 42,000 shares of company stock valued at $2,765,530 in the last quarter. Corporate insiders own 3.16% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the business. ETF Managers Group LLC grew its holdings in shares of Agios Pharmaceuticals by 15.7% during the 4th quarter. ETF Managers Group LLC now owns 1,592 shares of the biopharmaceutical company’s stock valued at $73,000 after purchasing an additional 216 shares during the last quarter. Wealthstreet Investment Advisors LLC grew its holdings in Agios Pharmaceuticals by 0.9% during the 1st quarter. Wealthstreet Investment Advisors LLC now owns 29,415 shares of the biopharmaceutical company’s stock worth $1,984,000 after acquiring an additional 250 shares during the last quarter. Advisor Group Inc. grew its holdings in Agios Pharmaceuticals by 33.1% during the 4th quarter. Advisor Group Inc. now owns 1,195 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 297 shares during the last quarter. California State Teachers Retirement System grew its holdings in Agios Pharmaceuticals by 0.4% during the 1st quarter. California State Teachers Retirement System now owns 80,018 shares of the biopharmaceutical company’s stock worth $5,396,000 after acquiring an additional 334 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Agios Pharmaceuticals by 14.2% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,457 shares of the biopharmaceutical company’s stock worth $159,000 after acquiring an additional 430 shares during the last quarter. 98.63% of the stock is currently owned by hedge funds and other institutional investors.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology for the treatment of cancer and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.